ORIC Pharmaceuticals, Inc. (ORIC)
Largest Insider Buys in Sector
ORIC Stock Price History Chart
ORIC Stock Performance
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively …
Insider Activity of ORIC Pharmaceuticals, Inc.
Over the last 12 months, insiders at ORIC Pharmaceuticals, Inc. have bought $0 and sold $1.35M worth of ORIC Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ORIC Pharmaceuticals, Inc. have bought $9.71M and sold $16.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 304,574 shares for transaction amount of $883,569 was made by Chacko Jacob (President and CEO) on 2022‑05‑11.
List of Insider Buy and Sell Transactions, ORIC Pharmaceuticals, Inc.
| 2024-03-06 | Sale | PRESIDENT AND CEO | 40,000 0.0599% | $16.21 | $648,380 | -40.59% | ||
| 2024-02-07 | Sale | PRESIDENT AND CEO | 26,042 0.0508% | $12.29 | $320,186 | -23.25% | ||
| 2024-02-06 | Sale | PRESIDENT AND CEO | 13,958 0.0268% | $12.12 | $169,160 | -21.22% | ||
| 2023-12-15 | Sale | President and CEO | 14,539 0.0246% | $8.58 | $124,813 | +3.45% | ||
| 2023-12-15 | Sale | Chief Financial Officer | 5,282 0.0089% | $8.58 | $45,338 | +3.45% | ||
| 2023-12-15 | Sale | Chief Medical Officer | 5,282 0.0089% | $8.59 | $45,351 | +3.45% | ||
| 2023-07-11 | Sale | President and CEO | 5,156 0.0115% | $8.01 | $41,287 | +11.10% | ||
| 2023-07-10 | Sale | President and CEO | 10,508 0.0235% | $8.01 | $84,212 | +10.89% | ||
| 2023-07-05 | Sale | President and CEO | 4,336 0.0098% | $8.01 | $34,711 | +12.39% | ||
| 2023-06-26 | Sale | President and CEO | 20,000 0.043% | $8.03 | $160,562 | +5.79% | ||
| 2022-12-15 | Sale | President and CEO | 6,137 0.0146% | $3.07 | $18,859 | +85.54% | ||
| 2022-12-15 | Sale | Chief Financial Officer | 2,227 0.0053% | $3.08 | $6,854 | +85.54% | ||
| 2022-12-15 | Sale | Chief Medical Officer | 2,227 0.0053% | $3.07 | $6,846 | +85.54% | ||
| 2022-05-11 | President and CEO | 304,574 0.8198% | $2.90 | $883,569 | +59.34% | |||
| 2022-03-31 | Chief Financial Officer | 60,000 0.1525% | $5.36 | $321,624 | -24.34% | |||
| 2022-03-23 | President and CEO | 42,873 0.1062% | $5.03 | $215,660 | -21.55% | |||
| 2021-09-15 | Sale | director | 682 0.0017% | $25.03 | $17,074 | -73.14% | ||
| 2021-09-15 | Sale | President and CEO | 3,736 0.0096% | $25.06 | $93,629 | -73.14% | ||
| 2021-09-14 | Sale | director | 706 0.0018% | $25.05 | $17,686 | -72.74% | ||
| 2021-09-14 | Sale | President and CEO | 4,420 0.0114% | $25.05 | $110,706 | -72.74% |
Insider Historical Profitability
| Chacko Jacob | PRESIDENT AND CEO | 728544 1.0328% | $10.08 | 2 | 28 | +18.89% |
| Piscitelli Dominic | Chief Financial Officer | 83809 0.1188% | $10.08 | 1 | 2 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 2212571 3.1365% | $10.08 | 1 | 14 | +4.15% |
| GORDON CARL L | director | 2212571 3.1365% | $10.08 | 1 | 14 | +4.15% |
Institutional Investor Ownership
| Nextech Invest | $72.68M | 7.84 | 5.29M | +23.33% | +$13.75M | 11.85 | |
| Fidelity Investments | $69.09M | 7.45 | 5.02M | -28.24% | -$27.19M | 0.01 | |
| Vr Adviser Llc | $60.42M | 6.52 | 4.39M | +80.97% | +$27.03M | 2.94 | |
| Frazier Life Sciences Management L P | $56.96M | 6.15 | 4.14M | +93.33% | +$27.5M | 2.57 | |
| Viking Global Investors | $55M | 5.93 | 4M | New | +$55M | 0.02 |